The Colchicine Conundrum | GenomeWeb

For the past few years, FDA has attempted to re-approve all the old drugs that made it to market before the current regulatory framework was in place. In an effort to catch up, the Wall Street Journal says, the regulatory body has been offering three years of market exclusivity to any company willing to do the clinical work and affirm the older drugs' efficacy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.